Average costs and incremental cost-effectiveness of urine sample collection
| Stage 1: first collection attempt | ||||||
| Collection method | Cost (GBP) | Incremental cost versus control (catheter) (GBP) | Effectiveness | Incremental effectiveness | ICER (GBP) | Average cost-effectiveness (cost per successful collection by designated method) (GBP) |
| Catheter | 23.38 | 0.9 | 25.98 | |||
| SPA | 16.63 | −6.75 | 0.44 | −0.46 | 14.67 | 37.80 |
| Voiding stimulation | 12.40 | −10.98 | 0.3 | −0.6 | 18.30 | 41.32 |
| Clean catch | 33.81 | 10.43 | 0.64 | −0.26 | Dominated * | 52.84 |
| Urine bag | 88.90 | 65.52 | 0.96 | 0.06 | 1091.98 | 92.60 |
| Stage 2: sample collected by catheterisation if initial attempt unsuccessful | ||
| Initial collection method | Cost (GBP) | Incremental cost per successful sample obtained versus control (GBP) |
| Catheter | 25.72 | |
| SPA | 28.76 | 3.05 |
| Voiding stimulation | 29.72 | 4.01 |
| Clean catch | 42.23 | 16.51 |
| Urine bag | 89.83 | 64.11 |
| Stage 3:obtaining an ultimately definitive sample | ||
| Initial collection method | Cost (GBP) | Incremental cost per definitive sample obtained versus control (GBP) |
| Catheter | 49.39 | |
| SPA | 51.84 | 2.45 |
| Voiding stimulation | 52.25 | 2.86 |
| Clean catch | 64.82 | 15.43 |
| Urine bag | 112.28 | 62.89 |
*Dominated refers to an intervention that is more costly and also less effective than the comparator.
ICER, incremental cost-effectiveness ratio; SPA, suprapubic aspirate.